Les microARN (miARN) sont de petits ARN non-codants dont la principale fonction est de réprimer l’expression génique en s’hybridant par complémentarité de séquence à leurs cibles ARN. L’activité des miARN est également régulée par leurs cibles qui entrent en compétition pour leur liaison. Certains de ces ARN compétiteurs endogènes (ARNce) résistent à la répression induite par le miARN et vont alors les séquestrer. Ils sont appelés éponges à miARN. La dérégulation des réseaux d’ARNce et des éponges à miARN est impliquée dans des processus pathologiques tels que le cancer. Au cours de ma thèse, nous nous sommes intéressés à la séquestration des miARN dans le mélanome cutané. Le mélanome provient de la transformation maligne du mélanocyte, une cellule spécialisée dans la production de pigment. S’il n’est pas pris en charge à temps, des métastases apparaissent et se disséminent rapidement dans l’organisme (ganglions, foie, poumons, cerveau, etc.). Des solutions thérapeutiques existent mais une faible proportion de patients y répondent de manière efficace nécessitant de nouvelles stratégies de traitement. Nous avons mis en évidence que l’ARN messager (ARNm) de TYRP1, gène spécifiquement exprimé dans le mélanocyte et donc le mélanome, porte le rôle d’éponge à miARN dans le mélanome métastatique. Ce rôle est indépendant de la fonction protéique de TYRP1. Nous avons déterminé que l’ARNm de TYRP1 séquestre le suppresseur de tumeurs miR-16 via des sites de liaison (MRE-16) non-canoniques. Les MRE-16 non-canoniques permettent à l’ARNm de TYRP1 de ne pas être dégradé par le miR-16 et le rendent donc plus stable dans la cellule de mélanome. La majorité du pool de miR-16 est ainsi séquestrée et ne peut donc plus réprimer ses cibles intervenant dans la prolifération cellulaire et la croissance tumorale in vivo. Afin de remettre en activité le miR-16 au sein de la cellule de mélanome, nous avons utilisé la technologie du « target site blocker » (TSB), un oligonucléotide antisens modifié ayant une forte stabilité et affinité pour sa cible. Le TSB, spécifique du MRE-16 de l’ARNm de TYRP1, entre en compétition pour la liaison à l’ARNm de TYRP1 avec le miR-16 pour permettre sa libération et son action sur ses cibles effectrices. Nous avons montré in vitro et in vivo via un modèle murin de xénogreffe de tumeur dérivée de patient que la stratégie du TSB est efficace contre le mélanome métastatique. Ces travaux ont permis l’identification d’un nouveau mécanisme oncogénique basé sur la séquestration de miARN et proposent une nouvelle stratégie de thérapie ciblée contre le mélanome métastatique. / MicroRNAs (miRNAs) are small non-coding RNAs. They fine tune gene-expression through specific complementary interaction with their RNA targets. The miRNA repressive function towards a given RNA is highly regulated and in part dependent on the abundance of its other targets competing for miRNA’s binding. Some of these competing endogenous RNAs (ceRNAs) can resist to miRNA-mediated RNA decay thereby sequestering miRNAs. They are named miRNA sponges. Deregulation of ceRNAs and miRNA sponges networks are implicated in many pathologic processes including cancer. My PhD work focused on miRNA sequestration in cutaneous melanoma. Melanomas arise from the malignant transformation of melanocytes; the skin-cell specialized in pigment production. Most melanoma undergoes metastatic evolution, with metastatic cells spreading rapidly in the entire organism (lymph node, liver, lungs, brain, etc.). Early and complete resection of primary in situ melanoma is thus determinant for patient outcome. Since 2010, potent therapeutic options have been developed. Unfortunately, patients ultimately develop resistance while some are non-responders. There is thus an urgent need to develop new therapeutic strategies to treat metastatic melanoma. We have identified that the Tyrosinase Related Protein 1 (TYRP1) mRNA function as a miRNA sponge. TYRP1 is specifically expressed in the melanocytic lineage. TYRP1 mRNA governs melanoma growth endorsing thereby a non-coding function. We demonstrated that TYRP1 mRNA sequesters the tumor suppressor miR-16 via non-canonical miRNA binding sites (MREs-16). Non-canonical miR-16 binding lacks mRNA decay function favoring TYRP1 mRNA stability and miRNA sequestration. Sequestered miR-16 can no more repress its canonical targets involved in cell proliferation and tumor growth. To reset miR-16’s activity and block melanoma growth, we used “Target Site Blocker” (TSB). TSBs are modified antisense oligonucleotides with enhanced stability and affinity to its target. We designed a TSB, named TSB-T3, overlapping specially TYRP1 non-canonical MRE-16. We first showed that TSB-T3 binds to TYRP1 mRNA and competes with miR-16. Freed miR-16 binds to its canonical targets inducing their decay. TSB-T3 blocks melanoma cell growth in vitro and in vivo, using patient-derived tumor xenograft. We thus showed for the first time that TSB’s strategy redirecting a tumor suppressor miRNA is a potent tool to monitor metastatic melanoma growth. Together my PhD work brings out a new oncogenic mechanism based on miRNA sequestration and proposes an original strategy of targeted therapy against metastatic melanoma.

Cutaneous melanoma is a very aggressive cancer with increasing incidence. It originates from transformed pigmented skin cells (melanocytes). The main risk factor for melanoma development is exposure to UV light and repeated sunburns. In approximately 10 % of cases, melanoma occurs on hereditary basis. Patients with cutaneous melanoma diagnosed in early stages have very good prognosis, with surgical resection of the primary tumour being mostly sufficient for treatment. In contrast, the advanced melanoma stages with metastases are often progressive and refractory to conventional therapies. Cutaneous melanoma is referred to as an immunogenic tumour that is frequently infiltrated by cells of the immune system. Tumours with immune cell infiltration show better prognosis. Spontaneous regression may occur. Over the last few years, progress has been made in the treatment of melanoma using checkpoints molecules (anti-CTLA-4 and anti-PD-1) to activate patients own immune system to recognize tumour lesions. In the tumour microenvironment, cytokines play an important role, enabling communication between cells and regulation of cell proliferation and migration and thus the tumour development. Cytokines (IL-2, IFNα) can be used in adjuvant therapy of melanoma. This work analysed levels of expressed cytokines in...

Major capside protein of Polyomaviridae family viruses is able to selfassemble into virus-like particle (VLP) even without the presence of minor proteins, bind exogenous DNA non-specifically and recognise the receptor on the cellular surface. These characteristics determine its use as vector in gene therapy or immunotherapy. It was discovered before that MPyV VLPs significantly stimulate immune system and have strong adjuvant effect. Chimeric VLP derived from mouse polyomavirus carrying exogenous antigene or epitop is supposed to elicit specifically targeted immune response after immunisation. The main obstacle is choice of immunogene that is strong enough to cause adequate immune response. The goal of this thesis was to construct chimeric particles carrying epitop of malignant melanoma, one of the most immunogenic tumours, on their surface, using methods of genetic engineering. For future research of particle's immunogenic properties three types of particles were developed - particles with human and mouse melanoma epitopes, respectively and control particles with ovalbumine epitop. For the purpose of production of chimeric protein was used baculovirus expression system. It was verified then, with the use of electron microscopy, that introduction of tumour antigen into one of surface loops of VP1...

Machine learning methods provide an opportunity to improve the classification of skin lesions and the early diagnosis of melanoma by providing decision support for general practitioners. So far most studies have been looking at the creation of features that best indicate melanoma. Representation learning methods such as neural networks have outperformed hand-crafted features in many areas. This work aims to evaluate the performance of convolutional neural networks in relation to earlier machine learning algorithms and expert diagnosis. In this work, convolutional neural networks were trained on datasets of dermoscopy images using weights initialized from a random distribution, a network trained on the ImageNet dataset and a network trained on Dermnet, a skin disease atlas.  The ensemble sum prediction of the networks achieved an accuracy of 89.3% with a sensitivity of 77.1% and a specificity of 93.0% when based on the weights learned from the ImageNet dataset and the Dermnet skin disease atlas and trained on non-polarized light dermoscopy images.  The results from the different networks trained on little or no prior data confirms the idea that certain features are transferable between different data. Similar classification accuracies to that of the highest scoring network are achieved by expert dermatologists and slightly higher results are achieved by referenced hand-crafted classifiers.  The trained networks are found to be comparable to practicing dermatologists and state-of-the-art machine learning methods in binary classification accuracy, benign – melanoma, with only little pre-processing and tuning.

La voie de signalisation Ras/MAPK (Ras/mitogen-activated protein kinase) régule une variété de protéines intracellulaires qui jouent un rôle important dans la croissance et la prolifération cellulaire. La régulation inappropriée de cette voie de signalisation conduit au développement de nombreux cancers comme le mélanome, qui est caractérisé par des mutations activatrices au niveau des gènes NRAS et BRAF. La protéine kinase RSK (p90 ribosomal S6 kinase) est un composant central de la voie Ras/MAPK, mais son rôle dans la croissance et la prolifération cellulaire n’est pas bien compris. RSK a été montrée pour participer à la résistance des mélanomes aux chimiothérapies, mais le mécanisme moléculaire reste encore à élucider. Nous montrons à l’aide d’un anticorps phospho-spécifique que MDM2 est phosphorylée en réponse à des agonistes et des mutations oncogéniques activant spécifiquement la voie Ras/MAPK. En utilisant des méthodes in vitro et in vivo, nous avons constaté que RSK phosphoryle directement MDM2 sur les Sérines 166 et 186, ce qui suggère que MDM2 est un substrat de RSK. La mutagénèse dirigée envers ces sites nous indique que ces résidus régulent l’ubiquitination de MDM2, suggérant que RSK régule la stabilité de MDM2 et de p53. De plus, nous avons observé que l’inhibition de RSK conduit à une augmentation du niveau protéique de p53 après un dommage à l’ADN dans les cellules de mélanomes. En conclusion, nos travaux suggèrent un rôle important de la protéine kinase RSK dans la régulation de MDM2 et de sa cible, p53. L’étude de ces mécanismes moléculaires aidera à mieux définir le rôle de RSK dans la croissance tumorale, mais également dans la résistance aux agents chimiothérapeutiques. / The Ras/mitogen-activated protein kinase (Ras/MAPK) signaling cascade regulates various intracellular targets involved in growth and proliferation. Inappropriate regulation of this pathway leads to many types of cancer, including melanomas, which are characterized by activating mutations in NRAS and BRAF. The protein kinase RSK (p90 ribosomal S6 kinase) is a central component of the Ras/MAPK pathway, but its role in cell growth and proliferation is not well understood. RSK has also been shown to participate in the resistance of melanoma cells to chemotherapy, but the mechanisms involved remain elusive. We show that MDM2 becomes phosphorylated in response to agonists and oncogenes of the Ras/MAPK pathway. Using in vitro and in vivo approaches, we found that RSK directly phosphorylates MDM2 at Ser166 and Ser186, suggesting that MDM2 is a bona fide RSK substrate. Site-directed mutagenesis indicated that these residues regulate MDM2 ubiquitination, suggesting that RSK regulates p53 function in an MDM2-dependent manner. Overexpression of active and inactive mutants of RSK revealed that this kinase regulates p53 stability, suggesting a role for RSK in the DNA damage response. Taken together, our results suggest an important role for RSK in the regulation of MDM2 and its target p53. In view of the role of p53 in the response to DNA-damaging agents, our results provide a potential mechanism involved in melanoma chemoresistance.

52 7.2 Souhrn v anglickém jazyce Malignant melanoma is the most lethal skin cancer whose incidence has been worldwide increasing. The prognosis of the disease is dependent on many factors - the effected locality, age, form of the tumor and the growth stage at which it was surgically removed. There has been no reliable adjuvant treatment available so far; although cytokins have been recently administered to high-risk patients. The accent is therefore put mainly on the timely detection and the relevant extent of surgical intervention whose degree depends on the stage of the disease. The result of the above mentioned facts is the necessity of an early diagnosis of new cases and permanent follow-up of the patients in whom melanoma has been already confirmed. The patients in the follow-up care are regularly checked, for the rest of their lives, at by the so called melanoma commissions, usually at dermatological clinics. The permanent contact with fact of the possible presence of the disease (information about the diagnosis, repeated follow-ups, waiting for the results of the examination) is stressful for these patients, although they become, to a certain extent, gradually adapted to stress. A good adaptation is however dependent also on the extent of social support, depression, the severity of the disease and...

No description available.

The reduction of intentional exposure to ultraviolet (UV) radiation is an important area of skin cancer prevention. Hillhouse et al. (Cancer 113:3257-3266, 2008) have developed an appearance-focused intervention with evidence of efficacy in lowering indoor tanning UV exposure in young women. In the current study, a subgroup approach was used to determine moderators of intervention efficacy. Undergraduate females in two regions of the United States (n = 362) were randomized into an intervention or control condition. Latent profile analysis was used to identify subgroups of indoor tanners based on patterns of indoor tanning motives. Intervention efficacy was examined within each subgroup. We found evidence for 4 subgroups of tanners: knowledgeable-appearance tanners, low-knowledge tanners, low-knowledge, relaxation tanners, and knowledgeable, low-appearance and lowrelaxation tanners. The intervention significantly reduced indoor tanning for the low-knowledge subgroup (34% of the sample). The utility of the subgroup approach in developing targeted behavioral skin cancer interventions is discussed.

Four known small molecule uracil-DNA glycosylase (UNG) inhibitors were synthesized and tested against human melanoma cells, IgR3 and MM200. They were found to be effective against cell proliferation at micromolar concentrations and to operate through a nonapoptotic mechanism. Thus, small molecules that target UNG may be useful as potential chemotherapeutic agents against human melanoma.

Given the prevalence and risk associated with indoor tanning among college students, university campuses constitute a prime target for skin cancer prevention. This report identifies the successes and challenges faced in promoting a campus-wide tan-free policy through the National Council on Skin Cancer Prevention (NCSCP) Indoor Tan-Free Skin Smart Campus Initiative. Beginning in February 2016, we communicated with university faculty or staff members who have participated in skin cancer prevention via education, clinical care, or research at 20 universities regarding the steps to adopt the tan-free policy. One campus, East Tennessee State University (ETSU), successfully fulfilled all criteria and implemented the policy change to become the first US Indoor Tan-Free Skin Smart Campus. The greatest challenge faced in recruiting campuses was gaining administrative support. Reported reasons for not adopting the policy change included wanting to wait for other schools to join first and not seeing it as a top priority. Despite the importance of improving skin cancer awareness and decreasing tanning among university students, we faced several challenges in promoting campus-wide policy change. We identify a need for research on effective ways to disseminate university health policies and increased involvement of healthcare providers in policy-related work.